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ABSTRACT 
Molecular monitoring of chronic myeloid leukemia patients using robust BCR-ABL1 tests standardized to 
the International Scale (IS) is key to proper disease management, especially when treatment cessation is 
considered.  Most laboratories currently utilize a time-consuming sample exchange process with 
reference laboratories for IS calibration.  A World Health Organization (WHO) BCR-ABL1  reference panel 
was developed (MR1-MR4), but access to the material is limited.  In this study, we describe the 
development of the first cell-based secondary reference panel that’s traceable to and faithfully 
replicates the WHO panel, with an additional MR4.5 level.  The secondary panel was calibrated to IS using 
digital PCR with ABL1, BCR, and GUSB as reference genes and evaluated by 44 laboratories worldwide.  
Interestingly, we found that > 40% of BCR-ABL1 assays showed signs of inadequate optimization such as 
poor linearity and suboptimal PCR efficiency.  Nonetheless, when optimized sample inputs were used, > 
60% demonstrated satisfactory IS accuracy, precision and/or MR4.5 sensitivity, and 58% obtained IS 
conversion factors from the secondary reference concordant with their current ones.  Correlation 
analysis indicated no significant alterations in %BCR-ABL1 results caused by different assay 
configurations.  More assays achieved good precision and/or sensitivity than IS accuracy, indicating the 
need for better IS calibration mechanisms. 
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INTRODUCTION 
The development of BCR-ABL1 tyrosine kinase inhibitors (TKIs), from the first generation imatinib to 
newer agents such as nilotinib and dasatinib, has enabled progressively deeper molecular responses in 
chronic myeloid leukemia (CML) patients undergoing TKI therapy.1, 2  Deeper molecular responses are 
defined as BCR-ABL1 levels of ≤ 0.01% (MR4) and ≤ 0.0032% (MR4.5) on the international reporting scale 
(IS) and are important milestones for patients considering treatment cessation.3  Other landmarks on 
the IS also represent different treatment decision thresholds and prognostic outcomes.4  For example, 
patients who reach 10% IS or below at 3 months after treatment have significantly higher rates of MR4.5 
by 5 years,5 and reaching 0.1% IS (major molecular response, MMR) by 12 months of treatment is 
predictive of subsequently achieving undetectable BCR-ABL1 levels.6  Thus, regular molecular monitoring 
using real-time reverse transcription quantitative polymerase chain reaction (RT-qPCR) is recommended 
for optimal disease management, and treatment decisions rely on achieving milestone molecular 
responses in the first year of therapy and beyond.2, 7   
Since treatment decisions are directly impacted by test results, accuracy and precision of BCR-ABL1 
assays across the entire measurement range is crucial for patient management, especially in patients 
with deep molecular responses when considering possible treatment cessation.  It is well known that 
high variability exists between RT-qPCR methods used in different laboratories.8, 9  The first international 
standardization attempt occurred in 2003, when different BCR-ABL1 assays used in the IRIS trial 
established IS based on 30 CML patient samples.10  Subsequently, a process for establishing a test-
specific IS Conversion Factor (CF) by exchanging 20-30 CML patient samples with a reference laboratory 
was developed.11  Although this process works well for laboratories with tests that show good stability 
over time, it is time-consuming, expensive and difficult to access for smaller laboratories.12, 13     
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In 2010, the “first International Genetic Reference Panel for quantitation of BCR-ABL mRNA” was 
developed as a primary standard for BCR-ABL1 assay IS calibration and accredited by the World Health 
Organization (WHO).14  The WHO panel is made of lyophilized K562 and HL-60 cell line mixtures, which 
allows the inclusion of cellular RNA extraction in the IS calibration against the 2 major BCR-ABL1 
breakpoints (e13a2 and e14a2), and carries 3 sets of nominal %BCR-ABL1 values using ABL1, BCR and 
GUSB as reference genes.  Due to restricted access, the WHO panel is currently only available to 
manufacturers of BCR-ABL1 test kits and secondary standards.13  The commercial secondary standards 
available to date are made of RNA,15, 16 thus RNA extraction is not included in the IS calibration process, 
except when  the standards are artificially spiked into the cell samples.  Furthermore, none of these are 
calibrated to the WHO panel against all 3 reference genes.        
In this study, we describe the successful development of the first cell-based BCR-ABL1 secondary 
reference panel that is traceable to and faithfully replicates the WHO panel in both raw materials 
(lyophilized K562 and HL-60 cell mixes) and manufacturing process, with the addition of a MR4.5 level.  
Nominal %BCR-ABL1 IS values were assigned to the secondary panel using reverse transcription droplet 
digital PCR (RT-ddPCR) against ABL1, BCR, and GUSB.  The secondary panel was successfully evaluated by 
45 different BCR-ABL1 assays in a subsequent international multi-center evaluation study. 
 
MATERIALS AND METHODS   
Manufacturing and IS calibration of secondary reference panel 
K562 (ATCC CCL-243) and HL-60 cells (ATCC CCL-240) (American Type Culture Collection, Manassas, 
Virginia, USA) were cultured, mixed, and lyophilized following methods described by White et al.14 with 
minor modifications (supplementary information).  Calibration to the WHO standards was performed as 
©    2016 Macmillan Publishers Limited. All rights reserved.
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described.14  IS calibration using ABL1 as a reference gene was conducted using 10 sets of WHO “first 
International Genetic Reference Panel for quantitation of BCR-ABL mRNA” panels (National Institute for 
Biological Standards and Control, South Mimms, UK).  Calibration using BCR and GUSB was conducted in 
a second study using another 10 sets of WHO panels.  On each day of 10 non-consecutive days, 1 WHO 
panel and 2 to 3 secondary panels were tested using RT-ddPCR in 4 replicates for the MR1 (10% BCR-
ABLIS) to MR4 (0.01% BCR-ABLIS) samples, and in 8 replicates for the MR4.5 sample to enhance assay 
precision.  Data analysis was performed using the statistical methods described by White et al.14   
 
Reverse transcription droplet digital PCR  
RNA extraction from the secondary panel was performed using RNeasy mini kits (Qiagen, Hilden, 
Germany).  Reverse transcription was performed using ABI High Capacity cDNA reverse transcription kit 
(Thermo Fisher Scientific, Waltham, Massachusetts, USA), and ddPCR was performed using 2X ddPCR 
Supermix (Bio-Rad, Hercules, California, USA) on the QX-100 or QX-200 ddPCR system (Bio-Rad).  All 
primer and probe sequences are listed in Table 1.  BCR-ABL1 and reference genes were run as singleplex 
reactions in separate wells.  To achieve optimal assay precision and avoid signal saturation, cDNA input 
for BCR-ABL1 per 20 µl reaction was 80 ng for the MR1 sample, 400 ng for the MR2 sample and 675 ng for 
samples ≤ MR3.  cDNA input for reference genes was 10 ng for all 3 reference genes.  For each RT-ddPCR 
run, wells with > 9025 accepted droplets were considered valid per the manufacturer’s 
recommendations.         
 
RESULTS  
Manufacturing and IS calibration of the WHO BCR-ABL1 secondary reference panel 
©    2016 Macmillan Publishers Limited. All rights reserved.
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We successfully manufactured > 12 000 vials of secondary BCR-ABL1 lyophilized cell reference panel, 
using the same K562 and HL-60 cell lines and following similar manufacturing procedures as the primary 
WHO panel (supplementary information).14  A MR4.5 level was added to the secondary panel to enable 
more accurate IS calibration at this critical level, as CML patients reaching this deep molecular response 
are increasingly  being considered for treatment cessation.  Quality control assessments indicated that 
the secondary panel had minimal residual moisture, excellent vial-to-vial homogeneity and > 2.5 years of 
real-time stability (supplementary information).   
To calibrate the secondary panel to the WHO first International Genetic Reference Panel for 
quantitation of BCR-ABL1 mRNA, we followed the study design described by White et al.,14 except that 
the sample size was doubled to strengthen the statistical power (supplementary information).  RT-
ddPCR was chosen as the calibration method due to its superior sensitivity, precision and absolute 
quantification capability compared to RT-qPCR.17, 18  At the time of this study, no commercially available 
BCR-ABL1 test utilized BCR or GUSB as reference genes.  We developed 3 sets of RT-ddPCR assays, 
including BCR-ABL1/ABL1, BCR-ABL1/BCR, and BCR-ABL1/GUSB, to enable IS calibration of the secondary 
panel against all 3 reference genes.  All RT-ddPCR assays were validated following a combination of 
industry best practices, Minimum Information for Publication of Quantitative Real-Time PCR 
Experiments (MIQE) and Clinical and Laboratory Standards Institute (CLSI) guidelines to ensure proper 
accuracy, precision, sensitivity and linearity were achieved (supplementary information ).19-22  Using 
methods described by White et al.,14 we determined the IS CF for the RT-ddPCR assays to be 0.93 for 
BCR-ABL1/ABL1, 1.85 for BCR-ABL1/BCR, and 1.28 for BCR-ABL1/GUSB.   
Each CF was subsequently applied to the empirical %BCR-ABL1 of the secondary panel measured by RT-
ddPCR to obtain the assigned %BCR-ABL1IS values (Figure 1 and Table 2a).  We found that the mean 
%BCR-ABL1 for each level of the secondary panel met all targeted BCR-ABL1 levels and were within 1.3-
©    2016 Macmillan Publishers Limited. All rights reserved.
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fold of the WHO standards values.  The assigned %BCR-ABL1IS of level E was 0.0038%, 0.0050% and 
0.0029% for ABL1, BCR and GUSB respectively, indicating that a MR4.5 level was successfully created.  
Moreover, the mean copy number of BCR-ABL1, ABL1, BCR and GUSB per ng of RNA measured using RT-
ddPCR was highly similar between the WHO and secondary panels (Table 2b).  This demonstrated that 
the secondary panel replicated the primary WHO panel faithfully, with the successful addition of a MR4.5 
level.   
 
Laboratory evaluation of the WHO BCR-ABL1 secondary reference panel 
Study Design 
The secondary panel was sent to 44 clinical laboratories from 24 countries worldwide for evaluation, 
including 34 laboratories from Europe (Supplementary Table 2).  One laboratory tested the panel with 2 
different BCR-ABL1 assays, resulting in a total of 45 BCR-ABL1 tests included in this report.  The 
laboratories were asked to conduct 2 studies with the secondary panel.  In Study 1, to determine the 
optimal sample input of the secondary panel specific for each BCR-ABL1 test, a standard curve 
experiment was run with Vial A (MR1) and Vial C (MR3) of the panel using 50 ng, 100 ng, 200 ng, and 400 
ng of RNA (for 1-step assays) or cDNA (for 2-step assays) input per PCR reaction; 3 replicates were run 
per sample at each input level (Figure 2a-b).  In Study 2, to assess the usability of the secondary panel 
and performance of the BCR-ABL1 tests, laboratories used the optimal sample input determined in 
Study 1 to test 3 sets of the panel on 6 different days (Figure 2c).     
 
Study 1: sample input optimization 
©    2016 Macmillan Publishers Limited. All rights reserved.
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The WHO panel did not offer recommendations on sample input for IS calibration.  Nonetheless, sample 
input outside of the linear dynamic range of a qRT-PCR assay might potentially lead to inaccurate 
results.  Thus, we designed a standard curve experiment to help laboratories determine the optimal 
sample input of the secondary panel for their BCR-ABL1 tests (Figure 2a-b).  Surprisingly, approximately 
half of the tests showed different %BCR-ABL1 results against different sample inputs of the same sample 
(P < 0.05), even when data from either the highest or lowest sample input were allowed to be removed 
based on auxiliary-pick-regression analysis (Figure 3 and supplementary information).  Among the 42 
assays that tested Vial A (MR1), 29% (12 of 42) showed decreasing %BCR-ABL1 with increasing sample 
input (Figure 3d), and 24% (10 of 42) showed increasing %BCR-ABL1 (Figure 3g and Supplementary 
Figure 2).  Among the 45 assays that tested Vial C (MR3), 22% (10 of 45) showed decreasing %BCR-ABL1 
with increasing sample input (Figure 3d), and 18% (8 of 45) showed increasing %BCR-ABL1 (Figure 3g 
and Supplementary Figure 3).       
In this study, we observed that the mean standard deviation (SD) in %BCR-ABL1 measurements from all 
45 assays was 0.2 log, which was mathematically equivalent to a 1.6-fold difference in the linear scale.  
Based on recommendations by Thiers et al., 1 SD (0.2 log) was considered the optimal cut-off for 
determining differences in measurements in this study.  Selecting 1 SD as the cut-off took into 
consideration the fact that a < 1 SD cut-off would require a substantially larger sample size to be 
considered statistically robust, whereas > 1 SD would increase the number of misclassifications.23  Thus, 
in this study, a mean difference of ≥ 0.2 log in %BCR-ABL1 value at different sample inputs by the same 
test was considered as beyond the inherent variability of an assay.  We found that among the assays 
that showed changing %BCR-ABL1 against different sample inputs, 55% (12 of 22) at MR1 and 78% (14 of 
18) at MR3 obtained results with ≥ 0.2 log difference.  Overall, these results showed that some BCR-ABL1 
tests were non-linear and might therefore yield statistically different %BCR-ABL1 results against 
different sample inputs.  To mitigate the risk of inaccurate %BCR-ABL1 measurements from using an 
©    2016 Macmillan Publishers Limited. All rights reserved.
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inappropriate sample input, it is highly recommended that laboratories standardize CML patient sample 
inputs by quantifyingthe extracted RNA prior to performing RT-qPCR.          
To further investigate the cause of the unstable %BCR-ABL1 measurements across different sample 
inputs, we calculated the PCR efficiency and efficiency ratio for each individual BCR-ABL1 and reference 
gene assay using the formula “Efficiency = -1 + 10(-1/slope)” (supplementary information).24  A well-
optimized PCR assay should have PCR efficiency between 0.9 and 1.1,25 which would result in a PCR 
efficiency ratio of approximately 1 between the BCR-ABL1 and reference gene assays.  Indeed, we found 
that most assays that successfully achieved stable %BCR-ABL1 across different sample inputs had a PCR 
efficiency close to 1 for both the BCR-ABL1 and reference gene assays, resulting in a mean efficiency 
ratio of 1.03 (n = 43; abnormal efficiency ratios of < 0 and > 10 were excluded from the analysis) (Figure 
3a-c).  Assays that showed decreasing %BCR-ABL1 against increasing sample input had a mean PCR 
efficiency ratio of 1.51 (n = 20) (Figure 3d-f), whereas assays that showed increasing %BCR-ABL1 had a 
mean PCR efficiency ratio of 0.63 (n = 16) (Figure 3g-i).  This indicated that the lack of stability in %BCR-
ABL1 against sample input was directly correlated with suboptimal PCR efficiency.  Surprisingly, BCR-
ABL1 and reference gene assays that were suboptimal in similar fashion could artificially cancel each 
other’s defects to achieve artificially stable %BCR-ABL1 results (Figure 3j-l).  Overall, these results 
illustrated that both the BCR-ABL1 and reference gene assays needed to be properly optimized and 
validated in order to achieve good quality %BCR-ABL1 testing.26, 27, 28     
Since different assays had different linear dynamic ranges, we observed a > 30-fold range of optimal 
sample input for the secondary panel calculated for the different BCR-ABL1 tests.  Interestingly, among 
the 31 laboratories that routinely quantified their CML patient sample inputs, the reported patient 
sample input was on average 2.4-fold higher than the calculated optimal input of the secondary panel, 
after 2 extreme outlier values of 11.6- and 48.3-fold were identified using robust regression analysis and 
©    2016 Macmillan Publishers Limited. All rights reserved.
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excluded from the calculation (supplementary information).  This was concordant with the fact that 
while the mean copy number of ABL1, BCR and GUSB per ng of RNA in the secondary panel was 674, 
1028 and 1245 (Table 2b), the mean copy per ng of human EDTA anticoagulated blood RNA was only 
289  for ABL1 (n = 40), 750 for BCR (n = 6), and 420 for GUSB (n = 5) (data not shown).  These results 
indicated that the optimal sample input of the secondary panel was approximately half of the patient 
sample input typically used by the laboratory in terms of ng RNA or cDNA.  Thus, when using the 
secondary panel, laboratories might consider using 2-fold less cDNA input per PCR reaction compared to 
CML patient samples to achieve similar copy numbers and avoid exceeding the linear dynamic range of 
their assay.  Nonetheless, it is recommended that laboratories perform a similar standard curve 
experiment to identify the optimal sample input specific for their assay prior to using the secondary 
panel for the first time.  The optimized sample input should maximize copy number detection but 
minimize potential PCR inhibition caused by carryover from the reverse transcription reactions.         
 
Study 2: performance of clinical BCR-ABL1 tests on the secondary panel  
A robust BCR-ABL1 test should demonstrate good IS accuracy, precision and sensitivity within statistical 
limits, especially at the lower disease levels.  In Study 2, laboratories were asked to use the optimal 
sample input determined in Study 1 to test 3 sets of the secondary panel on 6 different days, following 
the design previously used by White et al. (Figure 2c).14  Results from each assay were subsequently 
analyzed to assess accuracy, precision and sensitivity.  For IS accuracy, the overall mean %BCR-ABL1 
from all 45 assays, calculated using robust regression analysis to minimize effects of outliers, were highly 
concordant with the assigned values of the secondary panel (Table 3 and Supplementary Figure 5).  The 
mean ratios for all reference genes at all levels were within 1.5-fold or 0.16 log of the panel’s assigned 
values, with the exception of Vial D (MR4) for GUSB, which differed by 1.7-fold/0.24 log.  For results from 
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individual assays, 60% (27 of 45) obtained mean %BCR-ABL1 within 2-fold of the panel’s assigned values 
at all levels (Supplementary Figure 5).  The observed concordance was most likely due to 3 factors.  First, 
optimal sample input calculated in Study 1 was used for each assay, thus restricting the PCR reactions 
within the assay’s linear dynamic range.  Second, even though many different assay configurations were 
used by the laboratories (Supplementary Table 2), 60% (27 of 45) followed the EAC recommendations 
for the PCR primer design26 and 18% (8 of 45) used commercial BCR-ABL1 kits (Supplementary Table 2 
and Supplementary Figure 5), which are generally well optimized and validated.  Lastly, 51% (23 of 45) of 
assays were IS calibrated via sample exchange with the reference laboratory in Mannheim, Germany 
and 20% (9 of 45) with Adelaide, Australia.  This demonstrated that BCR-ABL1 tests can be effectively 
harmonized by using the same PCR primer designs and by standardizing the IS calibration process.  Thus, 
commercial availability of a common IS reference material could contribute to worldwide IS 
standardization.                 
Most clinical samples are typically run in only 1 or 2 replicates, which requires a high degree of assay 
precision to ensure accuracy of each of the final BCR-ABL1 test results.   To enable ≥ 95% confidence for 
the true value of a CML patient sample to be within 0.5 log on each side of the measured value, a SD of 
< 0.25 log for the BCR-ABL1 test is required.  Accordingly, if a sample is measured at MR4.5, there will be 
≥ 95% confidence that the true value of the sample is not above MR4 or below MR5.29  We calculated the 
intra-lab SD for each BCR-ABL1 test and noted that 84% (38 of 45) successfully achieved a SD of < 0.25 
log from MR1 to MR4.  For BCR-ABL1 tests that obtained ≥ 0.25 log SD, precision may be improved by 
performing further assay optimization and increasing the number of replicates per patient sample.28, 30   
For monitoring deep molecular response, good BCR-ABL1 assay sensitivity and precision are key 
performance characteristics.  In Study 2, we found that 93% (42 of 45) assays successfully detected all 
replicates at MR4, and 76% (34 of 45) detected all replicates at MR4.5.  To further understand how 
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sample input affected assay sensitivity and precision, we analyzed results from the 32 ABL1 assays since 
this provided the largest sample size.  Among the ABL1 assays, 56% (18 of 32) detected all replicates at 
MR4.5 and achieved < 0.25 log SD, 19% (6 of 32) detected all replicates but had ≥ 0.25 log SD, and 25% (8 
of 32) assays had at least 1 undetected replicate.  Logistic regression analysis showed a strong positive 
correlation between increased sample input and increased detection rate (P = 0.001).  In addition, the 
median ABL1 copy number per PCR reaction was 98 202 for laboratories that achieved good detection 
rate and precision, 74 923 for those that achieved good detection rate but suboptimal precision, and 29 
717 for those that had undetected replicates at MR4.5, further illustrating that an increased sample input 
could improve the sensitivity and precision of MR4.5 detection.  
The laboratories that participated in this study utilized diverse assay configurations for BCR-ABL1 testing 
(Supplementary Table 2).  To determine if assay configurations affected assay performance in terms of IS 
accuracy, precision, and sensitivity, we performed Bayesian average analysis and found no statistically 
significant relationship between assay performance versus choice of reference gene, RNA extraction 
method and the usage of commercial versus LDT assays.  Interestingly, among the assays that 
successfully achieved good accuracy (within 2-fold of assigned values), good precision (< 0.25 log SD) 
and good MR4.5 sensitivity (no undetected replicate), 82% (14 of 17) showed stable %BCR-ABL1 
measurements against sample inputs at MR3 in Study 1, compared to 46% (13 of 28) among assays with 
less optimal assay performance.  This illustrated that while BCR-ABL1 assays of different designs can 
perform equally well, proper PCR optimization is required to ensure good clinical performance.  
Interestingly, the number of assays that achieved good precision (84%) and MR4.5 (76%) sensitivity 
exceeded the number that achieved good IS accuracy (60%), indicating that there remains an unmet 
need for a simple and broadly available IS calibration mechanism.  
 
©    2016 Macmillan Publishers Limited. All rights reserved.
 17 
 
Calculating WHO IS CF from the secondary panel  
Using the assigned BCR-ABL1 IS values of the secondary panel, it was possible to calculate an IS CF 
traceable to the WHO panel for each test.  Prior to CF calculation, Bland-Altman analysis was performed 
for each assay as described by White et al.14 to assess if bias was linear across the %BCR-ABL1 range.  Of 
all the assays, 69% (31 of 45) showed no statistically significant trend in the Bland-Altman analysis, 
indicating that a valid CF could be calculated for these assays and compared to the laboratory’s current 
CF, most of which were obtained from sample exchange.  Mathematically, when the ratio between the 
assay’s current CF and the CF calculated from the secondary panel is < 0.63 or > 1.58, the resulting 
%BCR-ABL1 values will have a > 0.2 log difference (supplementary information).  Among the 31 assays, 
58% (18 of 31) achieved a CF ratio between 0.63 and 1.58, indicating that their current CF was 
equivalent to the CF from the secondary panel.  This was concordant with the fact that 60% of assays 
obtained mean %BCR-ABL1 within 2-fold of the panel’s assigned values.  This also indicated that the 
secondary panel can be effectively used to obtain IS CFs equivalent to sample exchange.         
 
DISCUSSIONS 
In this study, we successfully created the first cell-based BCR-ABL1 secondary reference panel that 
faithfully replicated the WHO BCR-ABL1 International Genetic Reference Panel in both raw material and 
manufacturing methods,14 with an additional MR4.5 level.  The secondary panel was manufactured under 
Good Manufacturing Practice and confirmed to have low residual moisture content, vial-to-vial 
homogeneity and > 2.5-year stability.  BCR-ABL1 IS values traceable to the WHO panel were assigned to 
the secondary panel using RT-ddPCR against ABL1, BCR, and GUSB.  Both the assigned IS values and 
©    2016 Macmillan Publishers Limited. All rights reserved.
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absolute copy numbers of the secondary panel were found to be highly concordant with the primary 
WHO standards.     
Many of the 44 laboratories that participated in the secondary panel evaluation currently act as a 
national reference laboratory for their country.  The panel was successfully processed by all laboratories, 
indicating that it is compatible with many different BCR-ABL1 test configurations.  Through a standard 
curve experiment, we found that close to half of the tests showed signs of inadequate PCR optimization 
such as poor linearity against different sample inputs and suboptimal PCR efficiency.  Interestingly, when 
a customized optimal sample input was used, 60% (27 of 45) of assays achieved mean %BCR-ABL1 values 
within 2-fold of the panel’s assigned values, 84% (38 of 45) achieved good precision (≤ 0.25 log SD) from 
MR1 to MR4, and 76% (34 of 45) achieved 100% detection rate down to MR4.5.  Three factors likely 
contributed to these excellent results: usage of a validated optimized sample input specific to the assay, 
the fact that 78% (35 of 45) assays used either the EAC primer design or a commercial kit, and that 71% 
(32 of 45) assays were IS calibrated via sample exchange with one of the two major international 
reference centers.  This indicated that using published assay designs and a harmonized IS calibration 
approach may lead to BCR-ABL1 test standardization.  Nonetheless, we noted that the number of assays 
that achieved good precision and sensitivity exceeded the number that achieved good IS accuracy, 
indicating that there remains an unmet need for a simple and broadly available calibration mechanism, 
such as this secondary panel, to ensure IS accuracy is maintained in laboratories over time.   
We also showed that different assay designs, including different reference genes, RNA extraction 
methods and usage of commercial kits versus LDTs did not affect assay performance.  Nonetheless, 
better PCR optimization correlated with better assay performance, and increased sample input 
improved detection rate and precision at MR4.5.  In addition to being a reference sample for IS 
calibration,14 the secondary reference material and its derivatives could also be used in assay analytical 
©    2016 Macmillan Publishers Limited. All rights reserved.
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validation and optimization.  For example, it can be used as standardized samples in External Quality 
Assessment (EQA) programs for proficiency testing,31 especially since nominal values (i.e. correct 
answers) are available for each member of the panel.  Second, it can become a source of positive control 
samples to be run alongside patient samples for quality assurance.  This can become especially powerful 
when multiple laboratories participate in a peer group quality control monitoring program, in which 
results from such positive control samples are compared and monitored regularly.  Lastly, the MR4.5 
sample in the reference panel can be used to validate the sensitivity and MR4.5 detection capability of an 
assay.   
In conclusion, a secondary reference panel traceable to the WHO panel with an additional MR4.5 level 
can provide easier access to IS calibration, as well as act as a tool for assay optimization, validation and 
quality assurance.               
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FIGURE LEGENDS 
Figure 1: The BCR-ABL1 secondary reference panel was calibrated to the WHO standards using RT-ddPCR 
against (a) ABL1, (b) BCR, and (c) GUSB for IS conversion (n = 40 from MR1 to MR4, n = 80 for MR4.5).  The 
IS CFs for the RT-ddPCR assays were determined to be 0.93 for the BCR-ABL1/ABL1 assay, 1.85 for the 
BCR-ABL1/BCR assay, and 1.28 for the BCR-ABL1/GUSB assay.  Blue dotted lines represent the nominal 
%BCR-ABL1 value of the WHO panel at different levels.  
Figure 2:  Study design for the international multi-center evaluation of the secondary panel, including (a) 
Study 1 for 1-step RT-qPCR tests, (b) Study 1 for 2-step RT-qPCR tests, and (c) Study 2.  
Figure 3: Examples of different assay results from Study 1 of the multi-center evaluation study.  A 
properly optimized assay should yield similar %BCR-ABL1 results at different sample inputs, and both the 
BCR-ABL1 and reference gene assays should have a PCR efficiency close to 1 (a-c).  Some assays showed 
decreasing %BCR-ABL1 measurements with increasing sample input (d-f), whereas others showed 
increasing %BCR-ABL1 measurements instead (g-i).  The PCR efficiency of these assays tended to be 
suboptimal (< 0.9 or > 1.1), resulting in disproportional increase of BCR-ABL1 or reference gene copy 
number with increasing sample input (e, f, h, i), which subsequently led to the unstable %BCR-ABL1 
measurements (d, g).  Occasionally, BCR-ABL1 and reference gene assays that were suboptimal in similar 
manner could cancel each other’s defects to achieve artificially stable %BCR-ABL1 measurements (j-l).  
Red lines represent the linear regression fit based on actual data, and blue lines represent what ideal 
data should resemble.               
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Table 1: Primer and probe sequences for the RT-ddPCR assays.
Gene Primer/Probe Sequence (5’ – 3’)
Forward primer CCGCTGACCATCAATAAGGAA
FAM MGB Probe AAGCCCTTCAGCGGC
Reverse primer CTGAGGCTCAAAGTCAGATGCTACT
Forward primer ACCACTGACGTGCCTGAGATG
FAM MGB Probe AGAGAGCGATCCTCTGG
Reverse primer GAGACACGGCAGGCTCATG
Forward primer CACTCAGCCACTGGATTTAAGC
FAM MGB Probe CCTGGAGGTGGATTC
Reverse primer CGCGTCTTTGCTTTATTCACAA
Forward primer ACGCAGAAAATACGTGGTTGG
FAM MGB Probe CTCATTTGGAATTTTGCCGAT
Reverse primer GCCGAGTGAAGATCCCCTTT
BCR-ABL1
ABL1
BCR
GUS
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Table 2: The BCR-ABL1 secondary reference panel was highly concordant with the WHO panel in 
(a) empirical and %BCR-ABL1IS values, and (b) copy numbers of ABL1, BCR-ABL1, BCR and GUSB per ng of RNA.
(a)
Panel Member
Mean 
Empirical 
%BCR-ABL1
Nominal %BCR-
ABL1
IS
Panel 
Member
Mean 
Empirical 
%BCR-ABL1 
Assigned %BCR-
ABL1
IS
4 (08/198) 11.2250 10.7469 A 13.7178 12.7575
3 (08/196) 1.2540 1.1672 B 1.2841 1.1942
2 (08/194) 0.1260 0.1112 C 0.1095 0.1019
1 (08/192) 0.0130 0.0118 D 0.0116 0.0108
E 0.0041 0.0038
4 (08/198) 9.8135 16.3129 A 11.5502 21.3678
3 (08/196) 0.8441 1.6627 B 0.7300 1.3505
2 (08/194) 0.0988 0.1753 C 0.0759 0.1404
1 (08/192) 0.0098 0.0195 D 0.0081 0.0150
E 0.0027 0.0050
4 (08/198) 6.5834 10.1235 A 9.1800 11.7504
3 (08/196) 0.5924 0.8295 B 0.6219 0.7960
2 (08/194) 0.0677 0.0749 C 0.0628 0.0804
1 (08/192) 0.0065 0.0071 D 0.0068 0.0087
E 0.0023 0.0029
(b)
BCR-ABL1 ABL1 BCR GUSB
A 103.27 754.55 973.44 1198.94
B 8.56 665.80 1058.25 1238.22
C 0.72 651.95 1012.51 1261.53
D 0.08 653.85 1079.15 1283.79
E 0.03 642.71 1017.74 1244.11
4 (08/198) 92.98 831.74 948.59 1380.43
3 (08/196) 9.75 778.56 1036.91 1454.12
2 (08/194) 0.99 784.95 1004.05 1390.83
1 (08/192) 0.10 785.90 1033.21 1388.23
Panel Member
Mean Copy Number Per ng RNA
Secondary 
Panel
WHO Panel
Secondary Panel
ABL1 0.93
BCR 1.85
GUSB 1.28
Reference 
Gene
RT-ddPCR IS 
Conversion 
Factor
WHO Panel
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Table 3: Summary results of the secondary panel international multi-center evaluation study.
WHO Panel 
Secondary 
Panel
Nominal Assigned Mean SD Minimum Maximum
4 (08/198) / A 10.7469 12.7575 11.4450 8.2225 3.6127 37.4603
3 (08/196) / B 1.1672 1.1942 1.1771 0.9994 0.4014 4.4109
2 (08/194) / C 0.1112 0.1019 0.1013 0.0931 0.0362 0.4553
1 (08/192) / D 0.0118 0.0108 0.0110 0.0232 0.0033 0.1323
NA / E 0.0038 0.0038 0.0038 0.0013 0.0159
4 (08/198) / A 16.3129 21.3678 21.3999 12.3547 13.6781 42.5295
3 (08/196) / B 1.6627 1.3505 1.7243 1.2662 1.0215 4.2655
2 (08/194) / C 0.1753 0.1404 0.1615 0.0863 0.0881 0.3025
1 (08/192) / D 0.0195 0.0150 0.0153 0.0105 0.0071 0.0302
NA / E 0.0050 0.0056 0.0047 0.0028 0.0134
4 (08/198) / A 10.1235 11.7504 8.9008 3.7900 4.5344 14.9359
3 (08/196) / B 0.8295 0.7960 0.7346 0.4133 0.3514 1.5494
2 (08/194) / C 0.0749 0.0804 0.0587 0.0351 0.0218 0.1149
1 (08/192) / D 0.0071 0.0087 0.0050 0.0033 0.0010 0.0106
NA / E 0.0029 0.0020 0.0018 0.0005 0.0054
%BCR-ABL1IS
Results From 45 BCR-ABL1  Assays
ABL 32
BCR 5
GUS 8
Reference 
Gene
Number of 
Labs
Vial (WHO / 
Secondary Panel)
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